The below Parliamentary question was asked by John Glen on 2016-02-29.
To ask the Minister for the Cabinet Office, how many people died from liver disease in (a) England and (b) each parliamentary constituency in the most recent year for which figures are available.
Mr Rob Wilson
The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.
The below Parliamentary question was asked by John Glen on 2016-07-12.
To ask the Secretary of State for Communities and Local Government, how much of the English language tuition fund his Department has spent since January 2016.
Mr Marcus Jones
As the first step in rolling out the new £20 million programme we have committed just over £3 million to enable six providers who delivered the Department’s previous community-based English language programme to provide new tuition to over 10,000 people by March next year.
We will shortly be issuing a new Prospectus, inviting applications to run the bulk of the new programme from 2017. The nature and targeting of that provision will be informed by Louise Casey’s Review of Integration and Opportunity.
We will monitor the new Programme to assess its effectiveness in meeting its objectives.
The below Parliamentary question was asked by John Glen on 2016-02-29.
To ask the Secretary of State for Health, what discussions NICE has had with the EU institutions on the proposed Joint Action 3 on health technology appraisals.
George Freeman
In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).
NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.
The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.
The below Parliamentary question was asked by John Glen on 2016-09-05.
To ask the Secretary of State for Education, whether her Department holds data on the (a) use and (b) prevalence of setting and streaming in schools in England.
Nick Gibb
In-school organisation, such as streaming or setting, is a matter for individual schools, and data is not collected or held by the Department on this matter.
The below Parliamentary question was asked by John Glen on 2016-02-29.
To ask the Secretary of State for Health, what representations he has received from NICE on the potential merits of a European relative effectiveness assessment to inform health technology appraisals.
George Freeman
In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).
NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.
The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.
The below Parliamentary question was asked by John Glen on 2016-10-11.
To ask the Secretary of State for Health, what plans (a) NICE and (b) NHS England has to issue a consultation on changes to the highly specialised technologies evaluation programme.
Nicola Blackwood
The National Institute for Health and Care Excellence and NHS England launched a joint consultation on 13 October 2016 setting out proposed changes to the arrangements for the evaluation and adoption of new technologies, including on the methodology for the evaluation of highly specialised technologies.
The below Parliamentary question was asked by John Glen on 2016-02-29.
To ask the Secretary of State for Health, what discussions he has had with NICE on its policy on a European relative effectiveness assessment for new drugs.
George Freeman
In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).
NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.
The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.
The below Parliamentary question was asked by John Glen on 2016-10-11.
To ask the Secretary of State for Health, whether he plans to appeal NICE’s draft guidance on asfotase alfa for treating paediatric-onset hypophosphatasia, issued in September 2016.
Nicola Blackwood
The National Institute for Health and Care Excellence (NICE) is currently evaluating the costs and benefits of asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia to determine whether it can be recommended for national commissioning by NHS England.
There has not yet been an opportunity for stakeholders to appeal NICE’s recommendations on the use of asfotase alfa for treating paediatric-onset hypophosphatasia. NICE published a second iteration of draft guidance for consultation on 22 September 2016 and the closing date for comments was 13 October 2016. NICE’s independent Evaluation Committee will now consider the comments received in response to the consultation before deciding on the next steps for the evaluation.
The below Parliamentary question was asked by John Glen on 2016-02-29.
To ask the Secretary of State for Health, how many hospital admissions due to liver disease there were in (a) England and (b) each parliamentary constituency in the last year for which figures are available.
Jane Ellison
The information requested is in the attached table.
The below Parliamentary question was asked by John Glen on 2016-10-11.
To ask the Secretary of State for Health, what steps his Department is taking to ensure that asfotase alfa is available on the NHS to all patients who may benefit from it.
Nicola Blackwood
The National Institute for Health and Care Excellence (NICE) is currently evaluating the costs and benefits of asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia to determine whether it can be recommended for national commissioning by NHS England.
There has not yet been an opportunity for stakeholders to appeal NICE’s recommendations on the use of asfotase alfa for treating paediatric-onset hypophosphatasia. NICE published a second iteration of draft guidance for consultation on 22 September 2016 and the closing date for comments was 13 October 2016. NICE’s independent Evaluation Committee will now consider the comments received in response to the consultation before deciding on the next steps for the evaluation.